A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Start Date
6/11/2024
Completion Date
8/31/2028
Summary
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Eligibility Criteria
Age Range: 45 years to 75 years
Interventions
AAV2-GDNF gene therapy
control surgery
Conditions
Locations
Mayo Clinic
Phoenix, Arizona 85054
United States
UCI Alpha Clinic (Neurology)
Irvine, California 92697
United States
Loma Linda University (Neurology)
Loma Linda, California 92354
United States
Loma Linda University (Surgical)
Loma Linda, California 92354
United States
University of California San Francisco (Neurology)
San Francisco, California 94143
United States
University of San Francisco (Surgical)
San Francisco, California 94143
United States
CenExel Rocky Mountain Clinical Research (Neurology)
Englewood, Colorado 80113
United States
Georgetown University (Neurology)
Washington D.C., District of Columbia 20057
United States
Parkinson's Disease and Movement Disorders Center of Boca Raton (Neurology)
Boca Raton, Florida 33486
United States
University of Florida
Gainesville, Florida 32608
United States
University of Miami
Miami, Florida 33125
United States
Orlando Health Neuroscience Institute
Orlando, Florida 32806
United States
Parkinson's Disease Treatment Center of Southwest Florida (Neurology)
Port Charlotte, Florida 33980
United States
Emory University (Surgical)
Atlanta, Georgia 30322
United States
Rush University Medical Center (Neurology)
Chicago, Illinois 60612
United States
University of Kansas Medical Center (Neurology)
Kansas City, Kansas 66103
United States
Massachusetts General Hospital (Neurology)
Boston, Massachusetts 02114
United States
Massachusetts General Hospital (Surgical)
Boston, Massachusetts 02114
United States
Michigan State University (Neurology)
East Lansing, Michigan 48824
United States
Quest Research Institute (Neurology)
Farmington Hills, Michigan 48334
United States
Cleveland Clinic Lou Ruvo (Neurology)
Las Vegas, Nevada 89106
United States
Columbia University
New York, New York 10032
United States
University of North Carolina (Neurology)
Chapel Hill, North Carolina 27514
United States
Duke Neurosurgery (Surgical)
Durham, North Carolina 27705
United States
Duke University (Neurology)
Durham, North Carolina 27710
United States
Ohio State University (Surgical)
Columbus, Ohio 43210
United States
University of Pennsylvania (Neurology)
Philadelphia, Pennsylvania 19104
United States
Vanderbilt University (Neurology)
Nashville, Tennessee 37232
United States
Texas Movement Disorder Specialists
Georgetown, Texas 78628
United States
Houston Methodist (Neurology)
Houston, Texas 77030
United States
Houston Methodist (Surgical)
Houston, Texas 77030
United States
University of Utah
Salt Lake City, Utah 84132
United States
EvergreenHealth Research Department (Neurology)
Kirkland, Washington 98034
United States
University of Wisconsin (Neurology)
Madison, Wisconsin 53705
United States
Charité - Universitätsmedizin Berlin (Surgical)
Berlin,
Germany
Philipps-Universität Marburg (Neurology)
Marburg,
Germany
Universitätsklinikum Tübingen (Neurology)
Tübingen,
Germany
Universitätsklinikum Tübingen (Surgical)
Tübingen,
Germany
Universitätsklinikum Würzburg (Neurology)
Würzburg,
Germany
Copernicus Podmiot Leczniczy, Szpital św. Wojciecha (Neurology)
Gdansk,
Poland
Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala (Neurology)
Katowice,
Poland
Mazowiecki Szpital Bródnowski (Neurology)
Warsaw,
Poland
Mazowiecki Szpital Bródnowski (Surgical)
Warsaw,
Poland
Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego CMKP (Neurology)
Warsaw,
Poland
North Bristol NHS Trust - Southmead Hospital (Neurology)
Bristol,
United Kingdom
University Hospital of Wales (Surgical)
Cardiff,
United Kingdom